16 results
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
2 Oct 23
Dawn of the neurotherapeutics era Dr. Jeremy Levin CEO & Chairman
12:15pm
PLATFORM & OV888* SOTICLESTAT OV329 OV329 KCC2 PLATFORM & OV350
Environmental advances enabled the cancer revolution in our lifetime Unclear genesis … Prevented progression of spontaneous recurrent seizures Increased seizure threshold against environmental stimuli Improved survival Protection from seizure
8-K
EX-1.1
fmym7f9fznu nnvo3
26 Aug 20
Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock
4:10pm
8-K
EX-1.2
q9lde0 b5vs
7 Oct 19
Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
9:29pm
8-K
EX-1.1
og8 s9jd9hr
7 Oct 19
Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
9:29pm
8-K
EX-99.1
5eregeobg
27 Jun 19
Regulation FD Disclosure
12:04pm
8-K
EX-1.1
7ik4otxbcyg vrhg0a
21 Feb 19
Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
4:53pm
8-K
EX-1.2
qkr4wcisj
21 Feb 19
Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
4:53pm
S-3
EX-1.2
m4jvqdt4
1 Jun 18
Shelf registration
5:14pm
- Prev
- 1
- Next